RetinAI Medical is a Swiss company that aims to improve eye care by empowering clinicians and supporting patients
throughout the medical examination process. Our vision is to transform reactive medicine to
preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD)
and Diabetic Retinopathy (DR). We will achieve this goal by removing technological barriers and
enabling high-throughput screening in the field of ophthalmology.
Our solutions rely on the latest advances in medical image analysis, ophthalmology and deep
learning. We have a unique team of scientists working to fully realise the capabilities
of artificial intelligence, and to integrate this technology
into the next generation of medical devices. Meet the Team!
What we do
RetinAI offers software solutions to empower eye care professionals during the evaluation of eye scans.
At its core lies a unique, interactive medical report that highlights and quantifies the
location, size and severity of pathological biomarkers in OCT, Fundus and Angiography images.
Through our highly intuitive user interface, ophthalmologists can determine the state of a
patient and monitor the progress of a treatment with a high degree of confidence.